Company profile for Perfuse Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. Our mission is to develop novel therapeutics to protect and improve the vision of patients with ocular diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1700 Owens Street, Suite 540 San Francisco, CA 94158
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-positive-results-from-phase-2-clinical-trials-in-glaucoma-and-diabetic-retinopathy-patients-302488857.html

PR NEWSWIRE
24 Jun 2025

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-positive-results-from-the-completed-phase-12a-clinical-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma-302446082.html

PR NEWSWIRE
06 May 2025

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-oral-presentation-on-per-001-intravitreal-implant-for-glaucoma-at-the-association-for-research-in-vision-and-ophthalmology-arvo-meeting-302433007.html

PR NEWSWIRE
21 Apr 2025

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-positive-visual-structural-and-safety-data-from-a-ph12a-trial-of-per-001-in-glaucoma-patients-at-the-american-glaucoma-society-meeting-302387598.html

PR NEWSWIRE
03 Mar 2025

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-initiation-of-enrollment-to-the-phase-2a-clinical-trial-of-per001-intravitreal-implant-in-diabetic-retinopathy-301892514.html

PR NEWSWIRE
03 Aug 2023

https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-initiation-of-enrollment-to-ph2a-portion-of-the-phase-12a-clinical-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma-301881971.html

PR NEWSWIRE
20 Jul 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty